Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver's Post-Meal secrets could unlock new fatty liver treatments

NCT ID NCT03849235

Knowledge-focused Sponsor: Copenhagen University Hospital, Hvidovre Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study investigates how the liver processes nutrients after a meal in healthy individuals and in patients with fatty liver disease or cirrhosis. Researchers will take blood samples and liver biopsies after fasting or eating a standardized meal, and after a glucagon injection. The goal is to understand the molecular changes in the liver, which may lead to better biomarkers and treatments for liver diseases.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Standardised meal and glucagon bolus
What this could lead to
If successful, this could identify new biomarkers and targets for treating fatty liver disease and cirrhosis.
What could go wrong
This is an observational study, not a treatment trial. It may not lead directly to new therapies, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

87 people

The number who actually took part.

Started

Mar 2019

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Healthy participants (WP1 , WP4 , WP5 ): Inclusion criteria: Healthy adults, 20 - 40 years old, non-smoker, BMI 20-25 kg/m2 , no chro-nical illnesses, no medication. Exclusion criteria: Blood donation within the past 3 months, acute illness within 2 weeks. NAFLD (WP2, WP6): Inclusion criteria: Patients with clinical diagnosis of NAFL and indication for liver biopsy. Exclusion criteria: Malignant disease, acute illness within the past 2 weeks. Cirrhosis (WP 3): Inclusion criteria: Patients with clinical diagnosis of cirrhosis and indication for liver biopsy. Exclusion criteria:Malignant disease, acute illness within the past 2 weeks. T2DM and NAFLD (WP7): Inclusion criteria: Patients with clinical diagnosis of T2DM and NAFL and indication for liver biopsy. Exclusion criteria: Malignant disease, acute illness within the past 2 weeks and use of insulin.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fatty liver disease Fibrosis metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cirrhosis Fatty liver

Contacts and locations

Locations

  • Gastrounit, Copenhagen University Hospital Hvidovre

    Hvidovre, Capital Region Denmark, 2650, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.